Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.

Lung cancer is a serious health problem and leading cause of death worldwide due to its high incidence and mortality. More than 80% of lung cancers feature a non-small cell histology. Over few decades, systemic chemotherapy and surgery are the only treatment options in this type of tumor but due to their limited efficacy and overall poor survival of patients, there is an urge to develop newer therapeutic strategies which circumvent the problems. Enhanced knowledge of translational science and molecular biology have revealed that lung tumors carry diverse driver gene mutations and adopt different intracellular pathways leading to carcinogenesis. Hence, the development of targeted agents against molecular subgroups harboring critical mutations is an attractive approach for therapeutic treatment. Targeted therapies are clearly more preferred nowadays over systemic therapies because they target tumor specific molecules resulting with enhanced activity and reduced toxicity to normal tissues. Thus, this review encompasses comprehensive updates on targeted therapies for the driver mutations in non-small cell lung cancer (NSCLC) and the potential challenges of acquired drug resistance faced in the field of targeted therapy along with the imminent newer treatment modalities against lung cancer.

• Publication year

  2015

• Venue

  Asian Pacific Journal of Cancer Prevention

• Publication date

  2015-06-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.7314/APJCP.2015.16.10.4147PMID 26028064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• in vitro and in vivo

  2016cited by this paper
• Non-small Cell Lung Cancer

  2016cited by this paper
• Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.

  2015cited by this paper
• Efficacy of first-line chemotherapy affects the second-line setting response in patients with advanced non-small cell lung cancer.

  2014cited by this paper
• ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

  2014cited by this paper
• Molecular pathways and therapeutic targets in lung cancer

  2014cited by this paper
• Curcumin suppresses proliferation and invasion in non-small cell lung cancer by modulation of MTA1-mediated Wnt/β-catenin pathway

  2014cited by this paper
• Effect of Withaferin A on A549 cellular proliferation and apoptosis in non-small cell lung cancer.

  2014cited by this paper
• Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive?

  2014cited by this paper
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

  2014cited by this paper
• Outcome of daily cisplatin with thoracic chemoradiotherapy in advanced non-small cell lung cancer patients with comorbid disorders: a pilot study.

  2014cited by this paper
• Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway.

  2014cited by this paper
• Immunotherapy for lung cancer: ongoing clinical trials.

  2014cited by this paper
• In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment.

  2014cited by this paper
• Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis.

  2014cited by this paper
• Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?

  2014cited by this paper
• Epidermal growth factor receptor mutations in lung adenocarcinoma

  2014cited by this paper
• Role of TGF-β signaling in curcumin-mediated inhibition of tumorigenicity of human lung cancer cells

  2013cited by this paper
• The impact of genomic changes on treatment of lung cancer.

  2013cited by this paper
• The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.

  2013cited by this paper
• Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.

  2013cited by this paper
• Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo

  2013cited by this paper
• Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.

  2013cited by this paper
• HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches.

  2013cited by this paper
• MET inhibition in lung cancer.

  2013cited by this paper
• Clinical observation and prognostic analysis of pemetrexed plus platinum as first-line treatment in patients with advanced non-small cell lung cancer.

  2013cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non- small-cell lung cancer: a meta-analysis of randomized controlled trials.

  2013cited by this paper
• Molecular biology of lung cancer.

  2013cited by this paper
• Curcumin inhibits human non-small cell lung cancer A549 cell proliferation through regulation of Bcl-2/Bax and cytochrome C.

  2013cited by this paper
• Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report

  2013cited by this paper
• The genetics and biology of KRAS in lung cancer

  2013cited by this paper
• EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

  2013cited by this paper
• Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

  2013cited by this paper
• Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Upregulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells

  2013cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

  2013cited by this paper
• Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

  2013cited by this paper
• CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

  2013cited by this paper
• Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

  2013cited by this paper
• BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.

  2013cited by this paper
• Anticancer effects of thymoquinone, caffeic acid phenethyl ester and resveratrol on A549 non-small cell lung cancer cells exposed to benzo(a)pyrene.

  2013cited by this paper
• Rare mutations in non-small-cell lung cancer.

  2013cited by this paper
• New targetable oncogenes in non-small-cell lung cancer.

  2013cited by this paper
• KRAS mutations in lung cancer.

  2013cited by this paper
• Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.

  2013cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012cited by this paper
• EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

  2012cited by this paper
• Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

  2012cited by this paper
• The Biological Role of PI3K Pathway in Lung Cancer

  2012cited by this paper
• RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer

  2012cited by this paper
• Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target

  2012cited by this paper
• Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

  2012cited by this paper
• Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.

  2012cited by this paper
• RET, ROS1 and ALK fusions in lung cancer

  2012cited by this paper
• XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib

  2012cited by this paper
• Immunotherapies for non-small-cell lung cancer and mesothelioma.

  2012cited by this paper
• Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

  2012cited by this paper
• Phosphatidylinositol 3-kinase could be a promising target in lung cancer therapy.

  2012cited by this paper
• Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice

  2012cited by this paper
• ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

  2012cited by this paper
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2012cited by this paper
• ROS1 rearrangements define a unique molecular class of lung cancers.

  2012cited by this paper
• Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

  2012cited by this paper
• Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.

  2012cited by this paper
• Abstract C189: CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations.

  2011cited by this paper
• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

  2011cited by this paper
• EGFR mutations and lung cancer.

  2011influential reference
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2011cited by this paper
• Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors.

  2011cited by this paper
• Crizotinib and testing for ALK.

  2011cited by this paper
• Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization with Correlation of ALK Protein Expression

  2011cited by this paper
• Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.

  2011cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

  2011cited by this paper
• Targeting Anaplastic Lymphoma Kinase in Lung Cancer

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• ALK-targeted therapy for lung cancer: ready for prime time.

  2011cited by this paper
• Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

  2011cited by this paper
• Active-specific immunotherapy for non-small cell lung cancer.

  2011cited by this paper
• Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy

  2011cited by this paper
• What is a systematic review?

  2011cited by this paper
• Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

  2011cited by this paper
• The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells.

  2011cited by this paper
• Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

  2011cited by this paper
• New driver mutations in non-small-cell lung cancer.

  2011cited by this paper
• Trilinolein inhibits proliferation of human non-small cell lung carcinoma A549 through the modulation of PI3K/Akt pathway.

  2011cited by this paper
• EGFR-mutated lung cancer: a paradigm of molecular oncology

  2010cited by this paper
• Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

  2010cited by this paper
• Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer

  2010cited by this paper
• Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

  2010cited by this paper
• KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.

  2010cited by this paper
• Cancer Statistics, 2010

  2010influential reference
• Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review.

  2010cited by this paper
• Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

  2009cited by this paper
• MET as a target for treatment of chest tumors.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

  2009cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009cited by this paper
• KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

  2009cited by this paper

• Artificial intelligence-based biomarkers for treatment decisions in oncology.

  2025cites this paper
• Synthesis of New Pyrazolo[1,5‐a]Pyrazin‐4(5H)‐One Derivatives and Effects on PI3K Protein Levels in A549 Lung Adenocarcinoma Cell Line

  2025cites this paper
• Soluble biomarkers as predictors of response to immunotherapy in Non-Small Cell Lung cancer (NSCLC)-insights from the tumor microenvironment perspective

  2025cites this paper
• Preclinical evaluation of targeted therapies for central nervous system metastases

  2024cites this paper
• Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression

  2023cites this paper
• Identification and clinical implications of circulating cancer associated fibroblasts in lung cancer patients

  2023cites this paper
• Ethnomedicinal Uses, Phytochemistry, and Anticancer Potentials of African Medicinal Fruits: A Comprehensive Review

  2023cites this paper
• Identifying druggable targets from active constituents of Azadirachta indica A. Juss. for non-small cell lung cancer using network pharmacology and validation through molecular docking.

  2023cites this paper
• Precision Targeting of Non-Small Cell Lung Cancer: Identifying Optimal Drug Targets and FDA-Approved Combinations for Enhanced Therapeutic Efficacy

  2023cites this paper
• Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment

  2022cites this paper
• Nonclinical Safety Pharmacology Study of the Herbal Product HAD-B1

  2021cites this paper
• Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial

  2021cites this paper
• Strategic targeting of non‐small‐cell lung cancer utilizing genetic material‐based delivery platforms of nanotechnology

  2021cites this paper
• Acute and Subchronic Toxicological Evaluation of the Herbal Product HAD-B1 in Rats

  2021cites this paper
• Chemotherapeutic Agents Increase PD-L1 Expression in A549 Lung Cancer Cell Line

  2021cites this paper
• An Overview of Non-Small Cell Lung Cancer and its Efficient clinical Management Technique

  2021cites this paper
• 5-Fluorouracil-Impregnated PLGA Coated Gold Nanoparticles for Augmented Delivery to Lung Cancer: in vitro Investigations.

  2021cites this paper
• Phyto-Phospholipid Conjugated Scorpion Venom Nanovesicles as Promising Carrier That Improves Efficacy of Thymoquinone against Adenocarcinoma Human Alveolar Basal Epithelial Cells

  2021cites this paper
• Pluronic-Coated Biogenic Gold Nanoparticles for Colon Delivery of 5-Fluorouracil: In vitro and Ex vivo Studies

  2021cites this paper
• Long non-coding RNA CCAT1 enhances human non-small cell lung cancer growth through downregulation of microRNA-218

  2020cites this paper
• Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer

  2020cites this paper
• Identification of novel bioactive molecules from garlic bulbs: A special effort to determine the anticancer potential against lung cancer with targeted drugs

  2020cites this paper
• AKTIVITAS SENYAWA 3,5,7- OCTATRIEN-2-OL, 2,6 DIMETHYL DARI EKSTRAK ZODIA SEBAGAI KANDIDAT OBAT ANTIKANKER PARU-PARU SECARA IN SILICO

  2020cites this paper
• Therapeutic potential of withaferin A against non-small cell lung cancer.

  2019cites this paper
• How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.

  2019cites this paper
• Biogenic synthesis of silver palladium bimetallic nanoparticles from fruit extract of Terminalia chebula – In vitro evaluation of anticancer and antimicrobial activity

  2019cites this paper
• Preparation of highly activated natural killer cells for advanced lung cancer therapy

  2019cites this paper
• CPSF3 is a promising prognostic biomarker and predicts recurrence of non-small cell lung cancer

  2019cites this paper
• OTT_A_201924 5077..5086

  2019cites this paper
• IL-24 Inhibits Lung Cancer Growth by Suppressing GLI1 and Inducing DNA Damage

  2019cites this paper
• Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells

  2018cites this paper
• p53 mediated transcriptional regulation of long non-coding RNA by 1-hydroxy-1-norresistomycin triggers intrinsic apoptosis in adenocarcinoma lung cancer.

  2018cites this paper
• Survival analysis in Caucasian pulmonary adenocarcinoma patients based on differential targets between Caucasian and Asian population

  2018cites this paper
• Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance

  2018cites this paper
• The Cytotoxic Constituents of Betula platyphylla and their Effects on Human Lung A549 Cancer Cells

  2018cites this paper
• Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.

  2017cites this paper
• Withaferin a synergistically enhances the effects of paclitaxel against lung cancer.

  2017influential citation
• DDA1, a novel oncogene, promotes lung cancer progression through regulation of cell cycle

  2017cites this paper
• Evidence for circulating cancer stem-like cells and epithelial–mesenchymal transition phenotype in the pleurospheres derived from lung adenocarcinoma using liquid biopsy

  2017cites this paper
• IL-24 modulates the high mobility group (HMG) A1/miR222 /AKT signaling in lung cancer cells

  2016cites this paper
• Inhibition of miR-103 reverses epithelial-mesenchymal transition and sensitizes lung A 549 cells to cisplatin in vitro and in vivo

  2016cites this paper
• End of Life Care in Oncology Critical Care Unit: Many Questions, Few Answers

  2016cites this paper
• The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)

  2016cites this paper
• Chemically synthesized CdSe quantum dots inhibit growth of human lung carcinoma cells via ROS generation

  2016influential citation